Comprehensive medication guide to Cinacalcet including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$0–$40 copay for generic cinacalcet under Medicare Part D (Tier 2–3); many in-center dialysis patients receive cinacalcet at no additional cost through the Medicare ESRD bundled payment.
Estimated Cash Pricing
$740–$800 retail for generic cinacalcet; as low as $18–$24 with GoodRx or SingleCare coupons for a 30-day supply. Brand Sensipar retails for approximately $795–$800.
Medfinder Findability Score
75/100
Summarize with AI
On this page
Cinacalcet (brand name: Sensipar) is a prescription oral medication in a drug class called calcimimetics. It was FDA-approved in 2004 — the first in its class — and is available as film-coated tablets in three strengths: 30 mg, 60 mg, and 90 mg. Generic versions became available in the United States around 2019, manufactured by multiple companies including Aurobindo Pharma.
Cinacalcet is primarily prescribed to adult patients on dialysis who have secondary hyperparathyroidism (SHPT) — a condition in which the kidneys' failure to regulate calcium and phosphorus causes the parathyroid glands to overproduce parathyroid hormone (PTH). It is also approved for hypercalcemia in patients with parathyroid carcinoma, and for primary hyperparathyroidism in patients who cannot undergo parathyroid surgery.
Cinacalcet must be taken with food or shortly after a meal. Tablets should always be swallowed whole — never crushed, split, or chewed. It is not approved for CKD patients who are not on dialysis, nor for pediatric patients.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Cinacalcet works as a positive allosteric modulator of the calcium-sensing receptor (CaSR) — a protein located on the surface of parathyroid gland cells. The CaSR acts like a sensor: when it detects adequate calcium in the blood, it signals the parathyroid gland to slow down PTH production. In chronic kidney disease, this receptor becomes desensitized, causing the parathyroid gland to overproduce PTH even when calcium levels are normal.
Cinacalcet binds to the CaSR at a site separate from calcium, but increases the receptor's sensitivity to calcium dramatically — making it far more responsive to existing calcium levels. The parathyroid gland then behaves as if calcium is higher than it actually is, rapidly reducing PTH secretion.
The downstream effects of reduced PTH include lower serum calcium, lower serum phosphorus, and reduced risk of bone disease (renal osteodystrophy) and vascular calcification. PTH levels begin to fall within hours of the first dose; steady-state levels are reached within about 7 days of regular dosing.
30 mg — tablet
Starting dose for secondary hyperparathyroidism in CKD on dialysis; also starting dose (twice daily) for parathyroid carcinoma and primary HPT
60 mg — tablet
Common titration dose for secondary SHPT; first titration step above 30 mg
90 mg — tablet
Higher titration dose for secondary SHPT; maximum single dose for parathyroid carcinoma (up to QID)
Cinacalcet is not listed on the FDA's official drug shortage database as of 2026. Generic cinacalcet became available around 2019, and multiple manufacturers now produce it, providing more supply resilience than during the brand-only era. Retail availability is generally good, with a findability score of 75 out of 100.
That said, many community retail pharmacies do not stock cinacalcet routinely because of its narrow prescribing population (primarily dialysis patients). Some pharmacies may need 1–2 business days to order it. Patients covered by Medicare Part D may also receive cinacalcet directly through their dialysis center at no additional cost under the ESRD bundled payment.
If your pharmacy is out of cinacalcet, medfinder calls pharmacies near you to find which ones can fill your prescription, then texts you results — saving you hours of calling on your own.
Cinacalcet is not a controlled substance and requires no special DEA prescribing authority. Any licensed prescriber in the United States can prescribe it. However, because cinacalcet is indicated for specific kidney and parathyroid conditions requiring specialist-level management and regular lab monitoring, it is primarily initiated by specialists.
Nephrologists — Most common prescribers; manage dialysis-dependent CKD with secondary SHPT
Endocrinologists — Prescribe for parathyroid carcinoma and primary hyperparathyroidism
Primary care physicians (PCPs) — May manage refills for stable patients under specialist guidance
Nurse practitioners (NPs) and physician assistants (PAs) — Can prescribe independently or collaboratively in nephrology and endocrinology practices
Telehealth nephrology services are increasingly available for established patients on stable cinacalcet regimens. Regular in-person lab monitoring (serum calcium, phosphorus, and PTH) is still required even with virtual appointments, so patients must have access to a local lab or dialysis center for blood draws.
No. Cinacalcet is not a controlled substance and is not scheduled by the DEA (Drug Enforcement Administration). It can be prescribed by any licensed healthcare provider — including physicians, nurse practitioners, and physician assistants — without special DEA prescribing authority.
There are no federal quantity limits, triplicate prescription requirements, or refill restrictions specific to cinacalcet. Standard prescription rules apply: it requires a valid prescription from a licensed provider and cannot be dispensed over the counter. Prescriptions may be called in, faxed, or sent electronically to the pharmacy.
The most common side effects of cinacalcet (occurring in ≥5% of patients in clinical trials):
Nausea (>25% of patients) — taking with food reduces this significantly
Vomiting (>25% of patients)
Diarrhea
Dizziness
Decreased appetite
Weakness and fatigue
Hypocalcemia (low calcium) — can cause tingling, muscle cramps, seizures, and life-threatening arrhythmias; serum calcium must be monitored within 1 week of starting or changing dose
QT interval prolongation and ventricular arrhythmia — linked to severe hypocalcemia
Seizures — reported in 1.4% of cinacalcet-treated patients in trials (vs 0.7% placebo)
Gastrointestinal bleeding — call your doctor if stools turn black or tarry
Heart failure worsening or hypotension — reported in patients with pre-existing cardiac conditions
Know what you need? Skip the search.
Etelcalcetide (Parsabiv)
IV calcimimetic given 3x/week at end of hemodialysis; more potent PTH reduction than cinacalcet; eliminates oral adherence issues; only for hemodialysis patients; cannot be used concurrently with cinacalcet
Paricalcitol (Zemplar)
Selective vitamin D receptor activator available in IV and oral forms; reduces PTH via vitamin D pathway; may raise calcium levels (opposite effect to cinacalcet); often used in combination with calcimimetics
Calcitriol
Active form of vitamin D; oldest treatment for secondary SHPT; inexpensive and widely available; higher risk of hypercalcemia and hyperphosphatemia compared to newer agents
Parathyroidectomy
Surgical removal of parathyroid glands; curative for severe or refractory SHPT; for patients who are surgical candidates and have failed medical management
Prefer Cinacalcet? We can find it.
Etelcalcetide (Parsabiv)
majorConcurrent use with cinacalcet is contraindicated — both are CaSR agonists and together can cause severe, life-threatening hypocalcemia. Wait at least 7 days after stopping cinacalcet before starting etelcalcetide.
Ketoconazole / Itraconazole (CYP3A4 inhibitors)
majorStrong CYP3A4 inhibitors significantly increase cinacalcet plasma levels. Dose adjustment of cinacalcet and close monitoring of serum calcium required.
Clarithromycin / Erythromycin (CYP3A4 inhibitors)
majorMacrolide antibiotics that inhibit CYP3A4, raising cinacalcet levels. Monitor calcium and consider cinacalcet dose reduction.
Carbamazepine (CYP3A4 inducer)
moderateInduces CYP3A4, accelerating cinacalcet metabolism and reducing its blood levels, potentially decreasing efficacy. Avoid or use an alternate anticonvulsant if possible.
CYP2D6 substrates (tricyclic antidepressants, beta-blockers, antipsychotics)
moderateCinacalcet is a strong CYP2D6 inhibitor. It may significantly increase blood levels of drugs metabolized by CYP2D6 — including amitriptyline, metoprolol, and thioridazine — potentially causing toxicity.
Cinacalcet has been a transformative therapy for dialysis patients with secondary hyperparathyroidism since its FDA approval in 2004. By acting on the calcium-sensing receptor to lower PTH, calcium, and phosphorus, it addresses the root cause of mineral bone disease in CKD — not just the symptoms.
With generic versions widely available since 2019, cinacalcet has become far more affordable and accessible. Cash prices with coupons can be as low as $18–$24 per month for the generic, making cost less of a barrier than in previous years. Most patients can access cinacalcet through their dialysis center, a specialty pharmacy, or a retail pharmacy — with or without insurance.
If you're having trouble finding cinacalcet at your pharmacy, medfinder calls pharmacies near you to find which ones have it in stock and texts you the results — so you spend less time searching and more time focused on your health.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini